These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 17925661

  • 1. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 2. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [Abstract] [Full Text] [Related]

  • 3. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Mar; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 4. Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy.
    Kim JG, Ku SY, Kim H, Chun SW, Suh CS, Choi YM.
    Menopause; 2009 Mar; 16(3):534-8. PubMed ID: 19225428
    [Abstract] [Full Text] [Related]

  • 5. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009 Mar; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 6. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Mar; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 7. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [Abstract] [Full Text] [Related]

  • 8. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.
    Steroids; 2005 Dec 01; 70(13):847-55. PubMed ID: 16005483
    [Abstract] [Full Text] [Related]

  • 9. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S.
    Pediatr Blood Cancer; 2006 Aug 01; 47(2):194-9. PubMed ID: 16358318
    [Abstract] [Full Text] [Related]

  • 10. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 Aug 01; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 11. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration.
    Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, Lubrano C, Bonaiuto M, D'Anna R, Cannata ML, Corrado F, Cancellieri F, Faraci M, Marini R, Adamo EB, Wilson S, Squadrito F.
    J Bone Miner Res; 2008 May 01; 23(5):715-20. PubMed ID: 18433304
    [Abstract] [Full Text] [Related]

  • 12. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL.
    Bone; 2005 Apr 01; 36(4):727-35. PubMed ID: 15781001
    [Abstract] [Full Text] [Related]

  • 13. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L.
    Alcohol Alcohol; 2006 Apr 01; 41(3):261-6. PubMed ID: 16476762
    [Abstract] [Full Text] [Related]

  • 14. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec 01; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 15. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang LZ, Xu MY, Chen JL.
    Zhonghua Nei Ke Za Zhi; 2004 Jun 01; 43(6):447-50. PubMed ID: 15312444
    [Abstract] [Full Text] [Related]

  • 16. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
    Oh KW, Rhee EJ, Lee WY, Kim SW, Oh ES, Baek KH, Kang MI, Choi MG, Yoo HJ, Park SW.
    Clin Endocrinol (Oxf); 2004 Aug 01; 61(2):244-9. PubMed ID: 15272921
    [Abstract] [Full Text] [Related]

  • 17. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007 Aug 01; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

  • 18. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction.
    Briana DD, Boutsikou M, Baka S, Hassiakos D, Gourgiotis D, Malamitsi-Puchner A.
    Neonatology; 2009 Aug 01; 96(2):132-6. PubMed ID: 19365143
    [Abstract] [Full Text] [Related]

  • 19. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H.
    J Hepatol; 2005 Dec 01; 43(6):973-83. PubMed ID: 16143421
    [Abstract] [Full Text] [Related]

  • 20. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.
    Osteoporos Int; 2006 Dec 01; 17(5):693-703. PubMed ID: 16435076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.